The efficacy of co-targeting of different components of the PI3K/PTEN/Akt/mTOR pathway with a novel dual PI3K/Akt inhibitor has been investigated in T-ALL. This evidence concerns the gene PIK3CA and acute lymphoblastic leukemia.